64
Participants
Start Date
June 29, 2020
Primary Completion Date
December 4, 2020
Study Completion Date
December 4, 2020
UNI911 inhalation 1% and intranasal spray 1%
Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
Placebo
The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
DanTrials ApS, Copenhagen
Lead Sponsor
UNION therapeutics
INDUSTRY